Blueprints of Life: Unlocking the Power of Modern Biotechnology
Articles

OPTIMIZING CAR T-CELL THERAPY: THE ROLE OF EZH2 INHIBITORS IN B CELL LYMPHOMAS

PDF
  • Ananyo Mazumdar,
  • Aditya Das,
  • Debjit De
Ananyo Mazumdar
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121.
Aditya Das
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121.
Debjit De
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121.

Published 2025-12-03

Keywords

  • CAR T-cell,
  • EZH2,
  • tumor microenvironment,
  • oncogenesis,
  • immunogenic

How to Cite

Mazumdar, Ananyo, et al. “OPTIMIZING CAR T-CELL THERAPY: THE ROLE OF EZH2 INHIBITORS IN B CELL LYMPHOMAS”. Swami Vivekananda University Press, Dec. 2025, pp. 90-97, https://swamivivekanandauniversitypress.com/index.php/svup/article/view/170.

Copyright (c) 2025 Swami Vivekananda University Press

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Abstract

CAR T-cell therapy has emerged as a potentially revolutionary treatment modality for refractory B-cell lymphomas, particularly in cases of DLBCL and FL. Despite huge success, more challenges are also seen in generating durable responses to the treatment approach. This article reviews the hope of EZH2 inhibitors, which can strengthen CAR T-cell efficacy. EZH2, a histone methyltransferase, is pivotal in germinal center B-cell lymphomas; gain-of-function mutations contribute to oncogenesis. Recent research indicates that EZH2 inhibition reprograms tumor cells to be more immunogenic but also modulates the tumor microenvironment by affecting the activity of regulatory T cells (Treg). Combining CAR T-cell therapy with EZH2 inhibitors is a promising avenue to overcome current therapeutic limitations.

DOI - https://doi.org/10.65525/SVUP.9788198800473.2025.90-97

PDF